Ketobutyrate compounds and compositions for treating age-related symptoms and diseases

Patent metadata

Field	Value
Publication number	US-10729668-B2
Application number	US-201515319589-A
Country	US
Kind code	B2
Filing date	Jun 29, 2015
Priority date	Jun 30, 2014
Publication date	Aug 4, 2020
Grant date	Aug 4, 2020

Abstract

Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.

First claim

What is claimed is:

1. A method for reducing infarct size of myocardial tissue in a human, comprising administering to the human a therapeutically effective amount of alpha-ketobutyrate or alpha-ketobutyric acid,
wherein the infarct size of myocardial tissue in the human after administration of the alpha-ketobutyrate or alpha-ketobutyric acid is reduced as compared to a control,
wherein the alpha-ketobutyrate or alpha-ketobutyric acid is administered as a daily dose of about 0.01-0.5 grams per kilogram body weight per day, and
wherein the alpha-ketobutyrate or alpha-ketobutyric acid is administered after a myocardial infarction in the human.

2. The method according to claim 1 , wherein the therapeutically effective amount is less than the amount of alpha-ketoglutarate or alpha-ketobutyric acid needed to produce a same observable difference.

3. The method according to claim 1 , wherein the therapeutically effective amount is less than half the amount of alpha-ketoglutarate or alpha-ketobutyric acid needed to produce a same observable difference.

4. The method according to claim 1 , wherein the therapeutically effective amount is about 1/16 the amount of alpha-ketoglutarate or alpha-ketobutyric acid needed to produce a same observable difference.

5. The method according to claim 1 , wherein the therapeutically effective amount is administered as several doses over a given period of time.

6. The method according to claim 1 , which comprises increasing alpha-ketobutyrate or alpha-ketobutyric acid levels in the human by about 30-60%.

7. The method according to claim 1 , wherein the therapeutically effective amount is administered as a daily dose for a week or more.

8. The method according to claim 1 , wherein alpha-ketobutyrate or alpha-ketobutyric acid is administered as a daily dose of about 0.1-0.2 grams per kilogram body weight per day.

9. The method according to claim 1 , which comprises increasing alpha-ketobutyrate or alpha-ketobutyric acid levels in the human by about 45-55%.

10. The method according to claim 1 , which comprises increasing alpha-ketobutyrate or alpha-ketobutyric acid levels in the human by about 50%.

11. The method of claim 1 , wherein the control is an infarct size of myocardial tissue in the human prior to administration of alpha-ketobutyrate or alpha-ketobutyric acid.

12. The method of claim 1 , wherein the control is an infarct size of myocardial tissue in an untreated human.

Assignees

• Univ California

Inventors

• Huang Jing
• Chin Randall M
• Fu Xudong
• Hwang Heejun
• Reue Karen
• Vergnes Laurent
• Jiang Meisheng
• Lomenick Brett E
• Yin Xiang
• Eghbali Mansoureh
• Li Jingyuan
• French Samuel Wheeler
• Khachatoorian Ronik

Classifications

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A23V2200/322

  having an effect on the health of the nervous system or on mental function · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title